Changes over time in high out-of-pocket health care burden in U.S. adults with diabetes, 2001-2011. by Li, Rui et al.
UCLA
UCLA Previously Published Works
Title
Changes over time in high out-of-pocket health care burden in U.S. adults with diabetes, 
2001-2011.
Permalink
https://escholarship.org/uc/item/47d68804
Journal
Diabetes care, 37(6)
ISSN
0149-5992
Authors
Li, Rui
Barker, Lawrence E
Shrestha, Sundar
et al.
Publication Date
2014-06-01
DOI
10.2337/dc13-1997
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Changes Over Time in High Out-of-Pocket Health Care Burden in 
U.S. Adults With Diabetes, 2001–2011
Rui Li1, Lawrence E. Barker1, Sundar Shrestha1, Ping Zhang1, O. Kenrick Duru2, Tony 
Pearson-Clarke1, and Edward W. Gregg1
1Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA
2David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Abstract
 OBJECTIVE—High out-of-pocket (OOP) costs can be an obstacle to health care access and 
treatment compliance. This study investigated trends in high OOP health care burden in people 
with diabetes.
 RESEARCH DESIGN AND METHODS—Using Medical Expenditure Panel Survey 2001–
2011 data, we examined trends in the proportion of people aged 18–64 years with diabetes facing 
a high OOP burden. We also examined whether the trend differed by insurance status (private 
insurance, public insurance, or no insurance) or by income level (poor and near poor, low income, 
middle income, or high income).
 RESULTS—In 2011, 23% of people with diabetes faced high OOP burden. Between 2001–
2002 and 2011, the proportion of people facing high OOP burden fell by 5 percentage points (P < 
0.01). The proportion of those who were publicly insured decreased by 22 percentage points (P < 
0.001) and of those who were uninsured by 12 percentage points (P = 0.01). Among people with 
diabetes who were poor and near poor and those with low income, the proportion facing high OOP 
burden decreased by 21 (P < 0.001) and 13 (P = 0.01) percentage points, respectively; no 
significant change occurred in the proportion with private insurance or middle and high incomes 
between 2001–2002 and 2011.
 CONCLUSIONS—The past decade has seen a narrowing of insurance coverage and income-
related disparities in high OOP burden in people with diabetes; yet, almost one-fourth of all people 
with diabetes still face a high OOP burden.
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Due to rising costs, increasing insurance premiums, and declining insurance benefits, health 
care has recently become less affordable. Stagnant incomes, which are partly due to the 
recession that started in 2007, have made this situation worse (1–4). Unaffordability can 
pose a barrier to seeking recommended health care. People with chronic diseases, such as 
diabetes, need extensive self-management support, medications, regular screening for signs 
of complications, and treatment of possible complications and comorbidities, all of which 
can increase out-of-pocket (OOP) costs of ongoing care in patients and their families 
compared with people without diabetes. Previous studies have shown that 45.1% of people 
with diabetes faced a high OOP burden (total family OOP spending on health care that 
exceeds 10% of family income). In comparison, the prevalence of high OOP burden in the 
overall population was 19.0% (1,5).
In recent years, several studies have reported an increase in the proportion of people in the 
general population facing a high health care–related OOP burden (2,6,7), but there have been 
no recent estimates of how the OOP burden has changed over time in those with diabetes. 
Furthermore, insurance coverage and income level have been strongly associated with OOP 
burden (1,8). In the current study, we used nationally representative data from 2001 to 2011 
to examine trends in high OOP burden from health care costs in people with diabetes aged 
18–64 years. We also examined how rates of high OOP burden differed by type of insurance 
coverage and income level.
 RESEARCH DESIGN AND METHODS
 Data Source
The analysis was based on 2001–2011 data from the Medical Expenditure Panel Survey 
(MEPS). MEPS is a nationally representative household survey of the U.S. civilian 
noninstitutionalized population sponsored by the Agency for Healthcare Research and 
Quality (9). It includes data on medical conditions, health status, health insurance coverage, 
and health care costs and spending. Rather than examining data 1 year at a time, we pooled 
adjacent years (2001–2002, 2003–2004, 2005–2006, 2007–2008, 2009–2010) to increase 
sample sizes, yielding more stable estimates. We used a single year’s data from 2011 
because 2012 data were unavailable at the time of this analysis. The study population 
comprised adults aged 18–64 years with self-reported diabetes (N = 13,128). We excluded 
people aged ≥65 years due to Medicare eligibility because this subset of the population often 
has different health care needs than younger people (1,8,10). However, we retained people 
aged <65 years who were covered by Medicare for disabilities or dialysis or as a recipient’s 
spouse, which accounted for ~16% of the total sample (11). We included this group to 
provide a representative sample of high OOP burden among all people with diabetes aged 
<65 years.
 Definition of the Outcome Variable
We used a widely accepted definition to measure high OOP burden, which takes into 
account not only OOP spending but also the ability to pay (1,8,12). OOP burden was 
calculated by dividing total family OOP spending on health care for all members in a given 
year by the family’s self-reported pretax income for that year. We used total self-reported 
Li et al. Page 2
Diabetes Care. Author manuscript; available in PMC 2016 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
OOP spending on health care services, including coinsurance, copayments, deductibles, and 
medical items; services not covered by insurance; and any portion of health insurance 
premiums paid OOP, including Medicare Part B premiums, if applicable. OOP burden was 
calculated at the family level and assigned to the individual in the family. This family-level 
measure was considered more appropriate for calculating OOP burden than individual-level 
measures because families often share resources and make decisions on resource allocation 
based on family needs. Thus, family income better reflects the standard of living than 
individual income, and family spending represents the family’s financial burden better than 
individual spending (1,13).
A person with diabetes is considered to have high OOP burden if the family total OOP 
spending on health care exceeds 10% of the family income. All costs were converted to 2011 
U.S. dollars based on the Consumer Price Index (14). Those in the top 0.1% of spending 
were omitted as outliers. Negative spending was discarded as implausible.
 Definition of Insurance and Income Categorization
Insurance status was categorized as privately insured, publicly insured (Medicare or 
Medicaid), or uninsured. We identified insurance coverage for each month in the 12 months 
before the time of the survey. Having no insurance coverage was defined as not having 
health insurance for the entire past year. To make insurance categories mutually exclusive, 
we designated the insurance type (private or public) with the longest coverage (1,8).
Income category was designated based on family income and the federal poverty level 
(FPL). The FPL is an annual, federally formulated dollar figure based on cost-of-living 
estimates and family size and composition. Poor was defined as having a family income 
<100% FPL, near poor as family income ≥100% but <125% FPL, low income as family 
income ≥125% but <200% FPL, middle income as family income ≥200% but <400% FPL, 
and high income as family income ≥400% FPL.
 Statistical Analyses
We estimated over time the proportion of people with diabetes aged 18–64 years with high 
OOP burden and repeated this analysis with stratification by insurance status and family 
income level. We used t tests to examine changes from the 2001–2002 baseline to the 
subsequent time periods. Although we compared findings across years, we did not formally 
test for trend, such as a successive differences test or testing the null hypothesis in which the 
Spearman correlation between time and proportion with a high OOP burden was 0. With 
only six time periods, such a test would have had such low power that its results would have 
been difficult to interpret.
To explore the drivers behind the changes in high OOP burden, we estimated the changes 
over time in OOP spending on different types of health care services (i.e., prescription drugs, 
including diabetic equipment and supplies; inpatient care; outpatient care; other care), 
annual insurance premiums paid OOP, and family income. We also calculated the OOP 
expenses for all health care services from individuals with diabetes. We stratified these 
analyses by insurance status because OOP burden was largely affected by insurance 
coverage.
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 Sensitivity Analyses
We conducted three sensitivity analyses to address three independent questions about the 
impacts of our methods. The first analysis tested the impact of changes in the MEPS data 
editing method for prescription drug data in 2007. MEPS made major changes to the data 
editing rule in 2007 and 2009 related to imputing the prescription drug price and expenditure 
information. These changes may have reduced measured OOP expenditures for prescription 
drugs compared with the previous editing method on the same data (15,16). We tested the 
impact of the data editing rule change in 2007 on the current study results by separately 
applying the 2007 editing rule and the pre-2007 rule to the 2006 MEPS prescription drug file 
data (internally created for MEPS). We then used the proportional difference in test results to 
adjust the 2007–2011 measures to be consistent with those from before 2007, assuming the 
same change effect would apply to data during 2007 and 2011. Unfortunately, we were 
unable to test the impact of the data editing rule in 2009 because the data were unavailable.
In the second sensitivity analysis, we excluded people covered by Medicare aged <65 years 
because receiving Medicare benefits might make this group intrinsically different from 
people in the same age range not receiving Medicare benefits. In the third sensitivity 
analysis, we excluded people who had had more than one type of insurance (private and 
public) over the previous year so that we could isolate the effect of each insurance type.
We used SAS version 9.2 statistical software for all analyses. To account for the complex 
sampling design of MEPS, survey procedures were used to determine a representative U.S. 
civilian noninstitutionalized population. Results were considered significant if P < 0.05.
 RESULTS
Overall, from 2001–2002 to 2011, there was a 5-percentage point decrease in the proportion 
of people with diabetes aged <65 years who faced high OOP burden (Fig. 1). From the 
2001–2002 baseline, at which 28% of people with diabetes faced high OOP burden, the 
proportion did not change significantly (P > 0.05 for all time period comparisons) through 
2008, but it decreased to 23% by 2009–2010 and 2011 (P < 0.01 for both).
After stratification, the baseline estimates of and changes in the proportion of people with 
diabetes with high OOP burden varied by insurance type (Fig. 1) and income level (Fig. 2). 
For privately insured people, high OOP burden increased from a 20% baseline in 2001–2002 
to 28% by 2005–2006 (P < 0.001), declined gradually during 2008–2010 (but was still 
higher than the 2001–2002 level [P < 0.05]), and reduced to 23% by 2011 (P > 0.05). For 
publicly insured people, from a 2001–2002 baseline of 43%, the proportion declined to 21% 
by 2011 (P < 0.05 for all time periods). For uninsured people, from a 2001–2002 baseline of 
36%, the proportion did not change significantly by 2007–2008 (P > 0.05), declined to 20% 
by 2009–2010 (P < 0.001), and increased to 24% by 2011 (P = 0.01) (Fig. 1).
Figure 2 shows trends in OOP burden in people with diabetes stratified by income level. For 
people in the poor and near-poor group, from a 2001–2002 baseline of 56%, the proportion 
declined to 35% (P < 0.001) by 2011. For the low-income group, from a 2001–2002 baseline 
of 47%, the proportion declined to 34% (P = 0.01) by 2011. For the middle-income group, 
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from a 2001–2002 baseline of 27%, there were no significant changes in the proportion by 
2011. For the high-income group, from a 2001–2002 baseline of 8%, the proportion 
increased to 15% by 2005–2006 (P = 0.001) and returned to 10% by 2011 (P > 0.05).
Table 1 shows the changes in the components of OOP burden in the overall population and 
by insurance type. In the overall study population, OOP costs paid as insurance premiums 
increased from 2001–2002 to 2003–2004 (P < 0.001) and remained at a high level in the 
later years of the study (P < 0.05 for all). On the other hand, annual family income and OOP 
expenses for health care services declined from the 2001–2002 baseline through 2009 and 
2011(P < 0.05).
By service type, OOP expenditure for prescription drugs declined through 2007 and 2011 
from the 2001–2002 level (P < 0.001 for all); the magnitude of reduction was 70–100% of 
that in overall health care services. OOP expenses for outpatient and other health care 
services declined from the 2001–2002 baseline through 2009 and 2011 (P < 0.05 for 
outpatient care in 2009–2010; P < 0.05 for both for other care). Inpatient care did not change 
over the study period (P > 0.5 for all) (Supplementary Fig. 1 and Table 1).
For people with private insurance, OOP spending on insurance premiums increased steadily 
from the 2001–2002 baseline level (P < 0.01 for all). OOP spending on all health care 
services and prescription drugs increased from the 2001–2002 baseline through 2003 and 
2006 (P < 0.05 for both) then declined through 2009 and 2011 (P < 0.01 for both).
For people with public insurance, OOP spending on health care services overall and 
prescription drugs decreased steadily from the 2001–2002 baseline (P < 0.001 for all). OOP 
spending on other health care expenses by publicly insured people also decreased from the 
2001–2002 baseline (P < 0.01 for both).
For uninsured people, OOP spending on prescription drugs did not change significantly from 
the 2001–2002 baseline through 2003 and 2008 but decreased by 2009–2010 and through 
2011 (P < 0.001 for both). OOP spending on outpatient care also decreased in 2009–2010 
and 2011 from the 2001–2002 baseline level (P < 0.01 for both) (Table 1).
People with diabetes account for more than one-half of the OOP expenses on health care 
services in the family. The trends in individual-level OOP expenses spent on people with 
diabetes are similar to the trends of the total family OOP expenses (Table 1).
Using the 2007 data editing rule change to process 2006 prescription data on reported family 
OOP spending on prescription drugs produced a result $147 less than the result using the old 
data editing rule on the same data. The data editing change resulted in a 2-percentage point 
decrease in the proportion of patients facing high OOP burden in the overall group, a 4-
percentage point decrease in the publicly insured group, a 1-percentage point decrease in the 
privately insured group, and no change in the uninsured group. By income level, the data 
editing change caused a 5-percentage point decrease in the proportion of high OOP burden 
in the poor and near-poor groups, a 1-percentage point reduction in the low-income group, a 
2-percentage point reduction in the middle-income group, and no change in the high-income 
Li et al. Page 5
Diabetes Care. Author manuscript; available in PMC 2016 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
group. When adjustments for the differences owing to the 2007 data editing change were 
applied to the 2007–2008 data, the general trend did not change.
After excluding families of people aged <65 years with Medicare coverage, the proportion 
of people with high OOP burden was 33% in 2001–2002 and 17% in 2011. OOP spending in 
people without Medicare was about one-half of the OOP spending in those with Medicare 
(Supplementary Table 1). When we limited the private insurance and public insurance 
coverage groups to only people with full 12-month coverage, the proportion with high OOP 
burden varied by 1–2 percentage points compared with findings from the primary analysis.
 CONCLUSIONS
The proportion of people with diabetes aged 18–64 years having high OOP burden declined 
between 2001–2002 and 2011. This was a result of a decline in the proportion of people with 
high OOP burden among those with public insurance, with no insurance, and in poor and 
near-poor or low-income groups. In the people with private insurance, the burden increased 
at first and then declined to the baseline level. There were no significant changes in the 
proportion of people facing high OOP burden in the middle- or high-income groups over the 
study period.
The findings have two major implications. First, the proportion of people with high OOP 
burden declined for those with public insurance or no insurance and for those in the poor and 
near-poor and low-income groups. Reducing OOP burden may improve the affordability of 
health care for these people because they could use the same amount of money to pay for 
more health care than before. Second, at the beginning of the study period, there was a 
substantial difference in high OOP burden between privately insured people and publicly or 
uninsured people and between people in the poor and near-poor and low-income groups and 
those in the high-income group. By the end of the study period, these differences 
disappeared or became smaller; that is, disparity in high OOP burden by insurance status and 
income level decreased. It is plausible that this difference might have resulted in a reduction 
in those disparities in health outcomes previously associated with differences in insurance 
and income level. Future studies could examine whether this reduced disparity in high OOP 
burden has indeed reduced disparity in access to health care and in health outcomes across 
the diabetic subgroups of the overall population aged <65 years.
The reduction in high OOP burden is mainly attributable to the reduction in OOP spending 
on prescription drugs. In those with public insurance, this reduction probably reflects 
Medicaid’s post-2001 cost-containment strategies, such as a preferred drug list (formulary), 
prior authorization requirement and quantity limitations for brand name drugs, and bundled 
payments (17–21). For example, by 2012, 48 states and the District of Columbia had a 
Medicaid formulary in place, which required higher copayment for nonformulary drugs 
(mostly higher-cost brand name drugs) than drugs on the formulary (mostly generic drugs) 
(20). These strategies gave patients and providers incentives to purchase or prescribe less-
expensive drugs. An earlier study found that the proportion of prescriptions filled with 
generic drugs increased dramatically among people with public insurance from ~43% in 
2003 to 55% by 2006 and then to >60% by 2008 (10).
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The 2006 introduction of Medicare Part D could partially explain the reduction in high OOP 
burden in families of publicly insured people with diabetes. Through the Part D program, 
Medicare provided insurance coverage for the first time for outpatient prescription drugs. 
Medicare Part D was associated with reduced OOP expenditure on prescription drugs in the 
Medicare population (22–24). Among people in our study population, this change affected 
the 16% who were aged <65 years receiving Medicare benefits (11).
Other factors may also have contributed to the decrease in OOP spending on prescription 
drugs among people with diabetes who had public insurance. For example, some states 
eliminated co-payments for their Medicaid plans (25). By 2003 and 2007, several drugs for 
treating diabetes and its risk factors, including metformin, angiotensin-converting enzyme 
inhibitors, and statins, went off patent, and their generic forms became available on the 
market (7,26,27). Between 2000 and 2006, at least 26 states authorized or started drug 
assistance programs to help people who could not afford prescription drugs. By 2009, 42 
states had such a program in place (28). The 2009 change in MEPS data editing methods for 
prescription drug files may also have contributed to the observed reduction for the 2009–
2010 and 2011 period because we observed a substantial decline in OOP spending on 
prescription drugs from the 2007–2008 level in all insurance-type groups. However, we 
could not determine the size of the impact resulting from the data editing rule change. Many 
of these changes could have affected all people with diabetes, not just those with public 
insurance. For example, in people without insurance or with private insurance, we also 
observed a reduction in OOP spending during 2009 and 2011.
Compared with the general U.S. population, publicly insured people with diabetes had a 
more substantial reduction in high OOP burden (2,6,7). As prescription drugs account for a 
larger part of OOP spending, this difference might have been because people with diabetes, 
who on average rely more heavily on prescription drugs, were more likely to respond to the 
cost-containment policies or subsidy programs (19). Prescription drugs accounted for a large 
portion of OOP health care spending. For people with diabetes, OOP spending on 
prescription drugs was >60% of the total OOP health care spending; in the general 
population, it was <40% (8,13). Thus, for people with diabetes, total OOP burden was more 
sensitive to changes in prescription drug costs than it was in the general population.
Although we observed an upward trend in the proportion of people in the privately insured 
group with high OOP burden between 2001–2002 and 2005–2006, the trend turned 
downward during 2007 and through 2011. This downward trend mainly resulted from a 
decline in OOP spending on prescription drugs among this group. A similar finding was also 
reported for the general population during 2007 and 2008 (7). It is unlikely that the 2007 
change in MEPS prescription data editing accounts for the reduction because the impact of 
the rule change was minimal in people with private insurance. Increased use of generic drugs 
might partially explain the decrease. From 2003 to 2008, the proportion of all prescriptions 
filled with generic drugs for privately insured individuals increased from 35 to 54%. 
However, the slope of increase was steepest for 2007–2008 (10).
One concern for the reduction in OOP spending we observed in the groups with public 
insurance and no insurance is the possible underuse of health care services during the 
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recession. However this explanation is unlikely because we found that total medical 
spending for all health care services did not decrease during the study period, as shown in a 
study by Cunningham (7). Rather, the proportion of expenses paid OOP declined, for 
example, for prescription drugs, outpatient care, and other health care services.
Trends in high OOP burden among people who are poor or near-poor were similar to those 
observed in people with public insurance. Trends in high OOP burden among people with 
high incomes were similar to those observed in people with private insurance. These 
findings were not surprising because there was substantial overlap between the poor and 
publicly insured groups and between the high-income and privately insured groups.
This study also provides an assessment of the impact of the change in the MEPS data editing 
rule for prescription drugs in 2007 on high OOP burden in 2007–2008. Although the impact 
might have been minimal in the general population, it was substantial among people with 
diabetes. Almost all the observed reductions in the proportions of people with high OOP 
burden in the publicly insured and poor and near-poor groups between 2005–2006 and 
2007–2008 were because of the data editing rule change in 2007. However, the downward 
trend in high OOP burden remained even after adjusting for the changes in data editing.
Although the percentage of people with diabetes aged <65 years experiencing a high OOP 
burden declined for the publicly insured and poor and near-poor groups, as of 2011, 23% of 
all people with diabetes still faced a high family OOP burden. Because the number of people 
with diabetes almost doubled from 1997 to 2007, the absolute number of people with 
diabetes at risk for high OOP burden likely also increased substantially (12).
The current study has several limitations. First, as in any survey, responses to MEPS could 
be subject to recall and social desirability biases. Second, MEPS changed its data editing 
rule on prescription drugs in both 2007 and 2009, which could plausibly have introduced 
bias into the process of estimating OOP spending for prescription drugs compared with 
estimates derived at using the old data editing rules. We tested the impact of the 2007 rule 
change in a sensitivity analysis. Unfortunately, we could not directly test how much of the 
reduced OOP spending on prescription drugs during the 2009–2011 period could be 
attributed to the data editing rule change in 2009 as opposed to a real change in spending. 
Third, we used family pretax (gross) income rather than disposable (net) income to calculate 
OOP burden. However, another study using the same data found that whether using pretax or 
disposable income, trends in OOP burden remained essentially the same (2). Fourth, the 
current OOP burden measures included both diabetes- and nondiabetes-related expenses for 
people with diabetes and their family members. It is not possible to attribute high OOP 
burden entirely to diabetes. However, the trends in OOP expenses on health care services in 
people with diabetes is consistent with the trend in OOP burden for the whole family. 
Finally, some people might have had both private insurance and public insurance within a 
single year. For grouping purposes, we assigned them to the insurance type under which they 
were covered for the longer part of the year. However, a sensitivity analysis using different 
definitions for insurance categories showed that the impact of this grouping method was 
minimal.
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In summary, in people with diabetes aged 18–64 years, we found a 5-percentage point 
decline between 2001 and 2011 in the proportion facing high OOP burden. When stratified 
by insurance status and family income, we found a decrease in disparity in OOP burden 
associated with insurance status and family income. However, the number of people with 
diabetes facing high OOP burden remained high. Because high OOP burden could be a 
barrier to treatment compliance and needed health care services and people with diabetes 
who do not receive adequate medical care are at substantial risk for costly and debilitating 
complications, policies that reduce this burden should be considered.
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Figure 1. 
Percentage of people aged 18–64 years with diabetes facing high OOP burden for health 
care in the overall population and stratified by type of insurance from 2001–2002 through 
2011. Error bars represent the 95% CIs.
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Figure 2. 
Percentage of people aged 18–64 years with diabetes facing high OOP burden for health 
care in the overall population and stratified by income level from 2001–2002 through 2011. 
Error bars represent the 95% CIs.
Li et al. Page 12
Diabetes Care. Author manuscript; available in PMC 2016 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Li et al. Page 13
Ta
bl
e 
1
M
ea
n 
an
nu
al
 fa
m
ily
 in
co
m
e 
an
d 
O
O
P 
bu
rd
en
 fr
om
 p
re
m
iu
m
s a
nd
 d
iff
er
en
t c
om
po
ne
nt
s o
f h
ea
lth
 c
ar
e 
ex
pe
ns
es
 fo
r p
eo
pl
e 
w
ith
 d
ia
be
te
s a
ge
d 
18
–6
4 
ye
ar
s 
by
 ty
pe
 o
f i
ns
ur
an
ce
 c
ov
er
ag
e 
fro
m
 2
00
1–
20
02
 th
ro
ug
h 
20
11
Sa
m
pl
e s
iz
e
M
ea
n 
an
nu
al
 
fa
m
ily
 in
co
m
e 
($)
M
ea
n 
an
nu
al
 
O
O
P 
fa
m
ily
 
pr
em
iu
m
&
 ($
)
M
ea
n 
an
nu
al
 to
ta
l f
am
ily
 O
O
P 
sp
en
di
ng
#  
($)
A
ll 
he
al
th
 c
ar
e 
se
rv
ic
es
†
Pr
es
cr
ip
tio
n 
dr
ug
s
In
pa
tie
nt
 c
ar
e
O
ut
pa
tie
nt
 ca
re
O
th
er
 ca
re
Pe
o
pl
e 
w
ith
 d
ia
be
te
s
O
ve
ra
ll
 
20
01
–2
00
2
2,
11
2
67
,3
85
1,
41
6
2,
51
1 
(31
)
1,
43
1 
(47
)
93
 (5
)
48
2 
(21
)
50
5 
(38
)
1,
56
7
 
20
03
–2
00
4
2,
07
9
64
,3
70
1,
74
4*
*
2,
52
7 
(29
)
1,
53
4 
(42
)
61
 (4
)
42
4 
(18
)
50
9 
(39
)
1,
58
9
 
20
05
–2
00
6
2,
42
2
62
,1
56
*
*
1,
64
2*
2,
47
6 
(28
)
1,
45
7 
(41
)
74
 (5
)
43
5 
(18
)
42
3 
(35
)
1,
54
0
 
20
07
–2
00
8
2,
54
8
64
,7
74
1,
63
7*
2,
32
4 
(26
)
1,
11
7*
*
*
 
(34
)
95
 (5
)
53
2 
(20
)
58
0 
(36
)
1,
42
1
 
20
09
–2
01
0
2,
54
1
62
,4
50
*
1,
81
3*
*
*
1,
72
6*
*
*
 
(23
)
82
2*
*
*
 
(32
)
96
 (6
)
40
1*
*
 
(18
)
40
7*
 
(33
)
1,
09
8*
*
*
 
20
11
1,
42
6
61
,6
79
*
1,
83
9*
1,
78
2*
*
*
 
(23
)
90
2*
*
*
 
(35
)
90
 (4
)
41
3 
(17
)
37
6*
*
 
(29
)
1,
18
0*
*
*
Pr
iv
at
el
y 
in
su
re
d
 
20
01
–2
00
2
1,
20
6
82
,8
61
1,
89
8
2,
34
8 
(28
)
1,
17
7 
(42
)
73
 (4
)
54
1 
(21
)
55
6 
(40
)
1,
36
0
 
20
03
–2
00
4
1,
06
3
80
,1
70
2,
46
4*
*
*
2,
61
1*
 
(28
)
1,
40
1*
*
 
(40
)
64
 (5
)
51
4 
(19
)
63
2 
(44
)
1,
52
6*
 
20
05
–2
00
6
1,
19
2
77
,8
49
*
2,
40
4*
*
*
2,
71
1*
*
 
(28
)
1,
44
8*
*
*
 
(40
)
81
9 
(6)
54
3 
(20
)
53
1 
(41
)
1,
61
2*
 
20
07
–2
00
8
1,
39
5
79
,9
76
2,
34
9*
*
2,
44
3 
(25
)
1,
06
9 
(33
)
86
 (4
)
64
3 
(20
)
64
5 
(38
)
1,
43
4
 
20
09
–2
01
0
1,
27
2
78
,6
08
2,
78
2*
*
*
2,
00
8*
*
*
 
(24
)
90
4*
*
*
 
(34
)
95
 (6
)
49
5 
(20
)
53
2 
(36
)
1,
20
3*
 
20
11
70
1
80
,0
76
2,
76
7*
*
*
1,
97
9*
*
 
(24
)
95
7*
*
*
 
(36
)
65
 (3
)
51
8 
(18
)
43
9*
 
(32
)
1,
25
6
Pu
bl
ic
ly
 in
su
re
d
 
20
01
–2
00
2
59
6
37
,2
38
65
4
2,
81
8 
(24
)
1,
97
6 
(44
)
11
6 
(2)
29
5 
(10
)
43
1 
(27
)
1,
94
4
 
20
03
–2
00
4
72
8
35
,0
09
58
5
2,
22
1*
 
(19
)
1,
71
7 
(34
)
44
 (2
)
18
9*
*
 
(7)
27
0*
 
(23
)
1,
58
2*
 
20
05
–2
00
6
84
6
36
,7
23
50
5
1,
96
2*
*
*
 
(18
)
1,
38
6*
*
*
 
(30
)
71
 (3
)
19
0*
 
(8)
26
5*
 
(19
)
1,
32
7*
*
*
 
20
07
–2
00
8
72
6
34
,7
66
55
0
1,
83
5*
*
*
 
(16
)
98
8*
*
*
 
(23
)
60
 (2
)
27
8 
(9)
50
8 
(28
)
1,
19
7*
*
*
 
20
09
–2
01
0
78
5
37
,9
55
50
6
1,
22
3*
*
*
 
(11
)
67
1*
*
*
 
(16
)
37
 (1
)
27
0 
(8)
24
5*
*
 
(21
)
85
9*
*
*
 
20
11
44
7
35
,4
86
65
3
1,
44
2*
*
*
 
(13
)
84
7*
*
*
 
(20
)
37
 (1
)
26
3 
(9)
29
6*
*
*
 
(20
)
91
0*
*
*
Diabetes Care. Author manuscript; available in PMC 2016 June 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Li et al. Page 14
Sa
m
pl
e s
iz
e
M
ea
n 
an
nu
al
 
fa
m
ily
 in
co
m
e 
($)
M
ea
n 
an
nu
al
 
O
O
P 
fa
m
ily
 
pr
em
iu
m
&
 ($
)
M
ea
n 
an
nu
al
 to
ta
l f
am
ily
 O
O
P 
sp
en
di
ng
#  
($)
A
ll 
he
al
th
 c
ar
e 
se
rv
ic
es
†
Pr
es
cr
ip
tio
n 
dr
ug
s
In
pa
tie
nt
 c
ar
e
O
ut
pa
tie
nt
 ca
re
O
th
er
 ca
re
Pe
o
pl
e 
w
ith
 d
ia
be
te
s
U
ni
ns
ur
ed
 
20
01
–2
00
2
31
0
44
,4
12
31
5
2,
78
0 
(68
)
1,
70
0 
(83
)
15
6 
(15
)
54
8 
(45
)
37
6 
(57
)
1,
93
3
 
20
03
–2
00
4
28
8
44
,7
07
38
4
2,
82
2 
(62
)
1,
86
5 
(82
)
87
 (1
2)
48
8 
(45
)
38
2 
(59
)
2,
00
2
 
20
05
–2
00
6
38
4
40
,2
07
33
9
2,
47
1 
(56
)
1,
68
1 
(76
)
44
 (4
)
48
3 
(36
)
24
5 
(47
)
1,
67
2
 
20
07
–2
00
8
42
7
48
,9
61
29
1
2,
68
4 
(50
)
1,
58
8 
(66
)
20
6 
(17
)
48
4 
(36
)
40
5 
(45
6)
1,
78
7
 
20
09
–2
01
0
48
4
41
,4
39
26
2
1,
49
4*
*
*
 
(41
)
76
1*
*
*
 
(57
)
20
7 
(22
)
25
7*
*
*
 
(32
)
26
9 
(45
)
1,
10
5*
*
*
 
20
11
27
8
40
,0
70
45
3
1,
68
1*
*
*
 
(42
)
78
3*
*
*
 
(62
)
31
7 
(17
)
29
3*
*
 
(37
)
28
7 
(35
)
1,
18
0*
*
*
D
at
a 
ar
e 
m
ea
n 
(%
) u
nle
ss 
oth
erw
ise
 in
dic
ate
d.
# P
er
ce
nt
ag
e 
re
pr
es
en
ts 
th
e 
re
la
tiv
e 
po
rti
on
 o
f e
x
pe
nd
itu
re
s p
ai
d 
O
O
P 
fro
m
 to
ta
l e
x
pe
nd
itu
re
s o
n 
th
is 
ty
pe
 o
f h
ea
lth
 c
ar
e 
se
rv
ic
e.
 &
Th
e 
pr
em
iu
m
 fo
r t
he
se
 p
ub
lic
ly
 in
su
re
d 
an
d 
th
e 
un
in
su
re
d 
in
di
v
id
ua
ls 
is 
lik
el
y 
to
 b
e 
fro
m
 o
th
er
 m
em
be
rs
 in
 th
e 
fa
m
ily
 b
ec
au
se
 it
 w
as
 th
e 
to
ta
l i
ns
ur
an
ce
 p
re
m
iu
m
 p
ai
d 
O
O
P 
fo
r a
ll 
th
e 
m
em
be
rs
 in
 th
e 
fa
m
ily
.
† T
he
 O
O
P 
ex
pe
nd
itu
re
 fo
r a
ll 
he
al
th
 c
ar
e 
se
rv
ic
es
, i
nc
lu
di
ng
 a
ll 
co
in
su
ra
nc
e,
 c
op
ay
m
en
ts,
 d
ed
uc
tib
le
s, 
an
d 
m
ed
ic
al
 it
em
s, 
an
d 
se
rv
ic
es
 n
ot
 c
ov
er
ed
 b
y 
in
su
ra
nc
e 
pa
id
 O
O
P 
in
 a
 y
ea
r, 
w
hi
ch
 e
qu
al
s t
he
 O
O
P 
ex
pe
nd
itu
re
 fr
om
 p
re
sc
rip
tio
n 
dr
ug
s, 
in
pa
tie
nt
 c
ar
e,
 o
ut
pa
tie
nt
 c
ar
e,
 a
nd
 o
th
er
 c
ar
e.
*
Si
gn
ifi
ca
nt
ly
 d
iff
er
en
t f
ro
m
 e
sti
m
at
es
 in
 2
00
1–
20
02
 a
t α
 
<
 0
.0
5.
*
*
Si
gn
ifi
ca
nt
ly
 d
iff
er
en
t f
ro
m
 e
sti
m
at
es
 in
 2
00
1–
20
02
 a
t α
 
<
 0
.0
1.
*
*
*
Si
gn
ifi
ca
nt
ly
 d
iff
er
en
t f
ro
m
 th
e 
es
tim
at
es
 in
 2
00
1–
20
02
 a
t α
 
<
 0
.0
01
.
Diabetes Care. Author manuscript; available in PMC 2016 June 20.
